Methods and compositions to inhibit symptoms associated with veisalgia

Abstract

The present invention relates to a method of reducing or preventing the symptoms associated with the intake of alcohol. The method comprises administering to a subject an effective amount of a pharmaceutical composition prior to alcohol intake. The pharmaceutical composition comprises a non-steroidal anti-inflammatory drug and a H 1 -antihistamine.

1 . A method of inhibiting the symptoms associated with intake of alcohol, comprising:
 administering to a subject an effective amount of a pharmaceutical composition prior to alcohol intake, wherein the pharmaceutical composition comprises:   a) a non-steroidal anti-inflammatory drug, and/or a salt thereof; and b) an H 1 -antihistamine,   wherein the symptoms associated with the intake of alcohol are inhibited.   
     
     
         2 . The method of  claim 1  wherein the alcohol is ethanol in the form of beverages. 
     
     
         3 . The method of  claim 1  wherein the non-steroidal anti-inflammatory drug is selected from the group consisting of: aspirin, ibuprofen, naproxen, diclofenac, diflunisal, etodolac, indomethacin, ketoprofen, ketorolac, meloxicam, nabumetone, oxaprozin, piroxicam, salsalate, sulindac, and tolmetin. 
     
     
         4 . The method of  claim 1  wherein the H 1 -antihistamine is selected from the group consisting of: fexofenadine, loratadine, cetirizine and desloratadine. 
     
     
         5 . The method of  claim 1  wherein the non-steroidal anti-inflammatory drug is naproxen sodium and the H 1 -antihistamine is fexofenadine. 
     
     
         6 . The method of  claim 5  wherein the amount of naproxen sodium is about 220 mg to about 880 mg, and the amount of fexofenadine is about 60 mg to about 120 mg. 
     
     
         7 . The method of  claim 6  wherein the naproxen sodium and the fexofenadine is combined in one unit dose. 
     
     
         8 . The method of  claim 6  wherein the naproxen sodium and the fexofenadine is in the form of a tablet, lozenge or chewing gum. 
     
     
         9 . The method of  claim 1  wherein the excessive intake of alcohol is an amount which provides a blood alcohol concentration of up to about 0.17%. 
     
     
         10 . The method of  claim 1  wherein the pharmaceutical composition is administered at most 60 minutes before intake of alcohol. 
     
     
         11 . The method of  claim 1  wherein the pharmaceutical composition is administered at most 5 minutes before intake of alcohol. 
     
     
         12 . The method of  claim 1  wherein the symptoms include fatigue and/or headache. 
     
     
         13 . The method of  claim 3  wherein the amount of ibuprofen is about 200 mg to about 800 mg. 
     
     
         14 . The method of  claim 3  wherein the amount of aspirin is about 325 mg to about 1000 mg. 
     
     
         15 . The method of  claim 5  wherein the amount of loratadine is about 10 mg to about 20 mg. 
     
     
         16 . The method of  claim 5  wherein the amount of cetirizine is about 5 mg to about 20 mg. 
     
     
         17 . The method of  claim 5  wherein the amount of desloratidine is about 5 mg to about 10 mg. 
     
     
         18 . The method of  claim 1  wherein the symptoms include thirst. 
     
     
         19 . A method of inhibiting the symptoms associated with intake of alcohol, comprising:
 administering to a subject an effective amount of a pharmaceutical composition prior to alcohol intake, wherein the pharmaceutical composition consists essentially of:   a) about 220 mg to about 880 mg of naproxen sodium, and about 60 mg to about 120 mg fexofenadine,   wherein the symptoms associated with the intake of alcohol are inhibited.   
     
     
         20 . A pharmaceutical composition comprising a) a non-steroidal anti-inflammatory drug selected from the group consisting of: aspirin, ibuprofen, naproxen, diclofenac, diflunisal, etodolac, indomethacin, ketoprofen, ketorolac, meloxicam, nabumetone, oxaprozin, piroxicam, salsalate, sulindac, and tolmetin; and b) a non-sedating H 1 -antihistamine selected from the group consisting of: fexofenadine, loratadine, cetirizine and desloratadine, wherein the pharmaceutical composition is in the form of an orally-dissolving tablet or lozenge.